Accessibility StatementSkip Navigation HONG KONG, Sept. 22, 2025 /PRNewswire/ -- Akeso Inc. (9926.HK)Â has announced that the first patient has been dosed in its registrational Phase II study (AK130-202), evaluating AK130, a fully independently developed TIGIT/TGF- bifunctional antibody fusion protein, in combination with ivonescimab (PD-1/VEGF bispecific antibody), for treating locally advanced or metastatic pancreatic cancer in patients who have failed up to two prior lines of systemic therapy. AK130 is t ...